Drugs that contain Sapropterin Dihydrochloride

1. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring Nov, 2024

(2 years from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin Nov, 2024

(2 years from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin May, 2025

(2 years from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring May, 2025

(2 years from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

US8003126 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

US7566462 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

US7566462

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

US8003126

(Pediatric)

BIOMARIN PHARM Stable tablet formulation May, 2026

(3 years from now)

US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin Nov, 2032

(10 years from now)

Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.